



A Pfizer Company

SAFETY DATA SHEET

Revision date: 09-Aug-2016

Version: 1.0

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Sufentanil Citrate Injection, USP CII (Hospira Inc.)

Trade Name: Sufentanil Citrate Injection, USP CII

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as analgesic

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

SAFETY DATA SHEET

Material Name: Sufentanil Citrate Injection, USP CII (Hospira Inc.)

Page 2 of 9

Revision date: 09-Aug-2016

Version: 1.0

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
HYDROCHLORIC ACID	7647-01-0	231-595-7	Skin Corr.1B (H314) STOT SE 3 (H335)	**
Sufentanil Citrate	60561-17-3	262-295-4	Acute Tox 2 (H300)2 (H361d)	0.005
SODIUM HYDROXIDE	1310-73-2	215-185-5	Skin Corr. 1A (H314)	**

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Water for Injection	7732-18-5	231-791-2	Not Listed	*

Additional Information:

* Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

- Eye Contact:** Rinse thoroughly with plenty of water, also under the eyelids. If irritation occurs or persists, get medical attention.
- Skin Contact:** Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.
- Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
- Inhalation:** Move to fresh air. If discomfort occurs, get medical attention.

Most Important Symptoms and Effects, Both Acute and Delayed

- Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
- Medical Conditions Aggravated by Exposure:** None known

Indication of the Immediate Medical Attention and Special Treatment Needed

- Notes to Physician:** None

5. FIRE FIGHTING MEASURES

Extinguishing Media: As for primary cause of fire.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

SAFETY DATA SHEET

Material Name: Sufentanil Citrate Injection, USP CII (Hospira Inc.)

Page 3 of 9

Revision date: 09-Aug-2016

Version: 1.0

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Restrict access to work area. Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Incompatible Materials: None known

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

HYDROCHLORIC ACID

ACGIH Ceiling Threshold Limit:	2 ppm
Australia PEAK	5 ppm
	7.5 mg/m ³
Austria OEL - MAKs	5 ppm
	8 mg/m ³
Belgium OEL - TWA	5 ppm
	8 mg/m ³
Bulgaria OEL - TWA	5 ppm
	8.0 mg/m ³
Cyprus OEL - TWA	5 ppm
	8 mg/m ³
Czech Republic OEL - TWA	8 mg/m ³
Estonia OEL - TWA	5 ppm
	8 mg/m ³
Germany - TRGS 900 - TWAs	2 ppm
	3 mg/m ³
Germany (DFG) - MAK	2 ppm
	3.0 mg/m ³

SAFETY DATA SHEET

Material Name: Sufentanil Citrate Injection, USP CII (Hospira Inc.)

Page 4 of 9

Revision date: 09-Aug-2016

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Greece OEL - TWA	5 ppm 7 mg/m ³
Hungary OEL - TWA	8 mg/m ³
Ireland OEL - TWAs	5 ppm 8 mg/m ³
Italy OEL - TWA	5 ppm 8 mg/m ³
Japan - OELs - Ceilings	2 ppm 3.0 mg/m ³
Latvia OEL - TWA	5 ppm 8 mg/m ³
Lithuania OEL - TWA	5 ppm 8 mg/m ³
Luxembourg OEL - TWA	5 ppm 8 mg/m ³
Malta OEL - TWA	5 ppm 8 mg/m ³
Netherlands OEL - TWA	8 mg/m ³
Poland OEL - TWA	5 mg/m ³
Portugal OEL - TWA	5 ppm 8 mg/m ³
Romania OEL - TWA	5 ppm 8 mg/m ³
Slovakia OEL - TWA	5 ppm 8.0 mg/m ³
Slovenia OEL - TWA	5 ppm 8 mg/m ³
Spain OEL - TWA	5 ppm 7.6 mg/m ³
Switzerland OEL - TWAs	2 ppm 3.0 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³

SODIUM HYDROXIDE

ACGIH Ceiling Threshold Limit:	2 mg/m ³
Australia PEAK	2 mg/m ³
Austria OEL - MAKs	2 mg/m ³
Bulgaria OEL - TWA	2.0 mg/m ³
Czech Republic OEL - TWA	1 mg/m ³
Estonia OEL - TWA	1 mg/m ³
France OEL - TWA	2 mg/m ³
Greece OEL - TWA	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Japan - OELs - Ceilings	2 mg/m ³
Latvia OEL - TWA	0.5 mg/m ³
OSHA - Final PELs - TWAs:	2 mg/m ³
Poland OEL - TWA	0.5 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	1 mg/m ³
Switzerland OEL - TWAs	2 mg/m ³

SAFETY DATA SHEET

Material Name: Sufentanil Citrate Injection, USP CII (Hospira Inc.)

Page 5 of 9

Revision date: 09-Aug-2016

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Sufentanil Citrate

Pfizer Occupational Exposure Band (OEB): OEB 5 (control exposure to <1ug/m³)

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. It is recommended that all operations be fully enclosed and no air recirculated.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:

Liquid

Color:

Colorless

Odor:

No data available.

Odor Threshold:

No data available.

Molecular Formula:

Mixture

Molecular Weight:

Mixture

Solvent Solubility:

No data available

Water Solubility:

Soluble

pH:

3.5-6

Melting/Freezing Point (°C):

No data available

Boiling Point (°C):

No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

HYDROCHLORIC ACID

No data available

SODIUM HYDROXIDE

No data available

Sufentanil Citrate

No data available

Water for Injection

No data available

Decomposition Temperature (°C):

No data available.

Evaporation Rate (Gram/s):

No data available

SAFETY DATA SHEET

Material Name: Sufentanil Citrate Injection, USP CII (Hospira Inc.)

Page 6 of 9

Revision date: 09-Aug-2016

Version: 1.0

Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: 0.9961
Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): No data available
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: None
Conditions to Avoid: None known
Incompatible Materials: None known
Hazardous Decomposition Products: None known

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.
Long Term: Animal studies have shown a potential to cause adverse effects on the fetus.
Known Clinical Effects: The most common adverse effects seen during clinical use of this drug include drowsiness, nausea, decrease in blood pressure (hypotension), increase in blood pressure (hypertension), respiratory depression, musculoskeletal system rigidity, decreased heart rate (bradycardia).

Acute Toxicity: (Species, Route, End Point, Dose)

HYDROCHLORIC ACID

Rat Oral LD50 238-277 mg/kg

Sufentanil Citrate

Rat IV LD50 17.9 mg/kg
Mouse IV LD50 18.7mg/kg
Dog IV LD50 10.1-19.5mg/kg

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Sufentanil Citrate

Embryo / Fetal Development Rat No route specified 2.5 times human dose LOAEL Embryotoxicity
Embryo / Fetal Development Rabbit No route specified 2.5 times human dose LOAEL Embryotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

HYDROCHLORIC ACID

SAFETY DATA SHEET

Material Name: Sufentanil Citrate Injection, USP CII (Hospira Inc.)

Page 7 of 9

Revision date: 09-Aug-2016

Version: 1.0

11. TOXICOLOGICAL INFORMATION

Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vivo Micronucleus Rat Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

HYDROCHLORIC ACID

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

SAFETY DATA SHEET

Material Name: Sufentanil Citrate Injection, USP CII (Hospira Inc.)

Page 8 of 9

Revision date: 09-Aug-2016

Version: 1.0

15. REGULATORY INFORMATION

HYDROCHLORIC ACID

CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb 2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	500 lb
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	5000 lb
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5 Schedule 6
EU EINECS/ELINCS List	231-595-7

Water for Injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

Sufentanil Citrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	262-295-4

SODIUM HYDROXIDE

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb 454 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5 Schedule 6
EU EINECS/ELINCS List	215-185-5

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

SAFETY DATA SHEET

Material Name: Sufentanil Citrate Injection, USP CII (Hospira Inc.)

Page 9 of 9

Revision date: 09-Aug-2016

Version: 1.0

Acute toxicity, oral-Cat.2; H300 - Fatal if swallowed

Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage

Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Revision date: 09-Aug-2016

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet